Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Oct;7(5):971-972.
doi: 10.1016/j.euo.2024.06.001. Epub 2024 Jun 29.

Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing and Existing Data Suggest How to Mitigate Toxicity

Lisa M Cordes  1 , Fatima Karzai  1 , Ravi A Madan  2
Affiliations
Editorial

Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing and Existing Data Suggest How to Mitigate Toxicity

Lisa M Cordes et al. Eur Urol Oncol. 2024 Oct.

Abstract

Data from the EMBARK trial demonstrate the potential of enzalutamide monotherapy as an effective treatment for biochemically recurrent prostate cancer (BCR) without the side effects of testosterone-lowering therapy. Unfortunately, concerns about gynecomastia and how to manage this treatment-related toxicity have diminished enthusiasm. Existing data may offer an alternative scheduling strategy for enzalutamide monotherapy in BCR.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors have nothing to disclose.

References

    1. Xtandi Pharma A. (enzalutamide) package insert. Northbrook, IL: Astellas Pharma US, Inc; 2023.
    1. Freedland SJ, de Almeida LM, De Giorgi U, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med 2023;389:1453–65. 10.1056/NEJMoa2303974. - DOI - PubMed
    1. Madan RA, Karzai F, Donahue RN, et al. Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. J Immunother Cancer 2021;9:e001556. 10.1136/jitc-2020-001556. - DOI - PMC - PubMed
    1. Freedland SJ, Gleave M, De Giorgi U, et al. Enzalutamide and quality of life in biochemically recurrent prostate cancer. NEJM Evid 2023;2: EVIDoa2300251. 10.1056/EVIDoa2300251. - DOI - PubMed
    1. Shore ND, Sieber PR, Gleave M, et al. Outcomes of men with high-risk biochemically recurrent prostate cancer who suspend enzalutamide monotherapy treatment in the phase 3 EMBARK study. J Clin Oncol 2024;42(4 Suppl):15. 10.1200/JCO.2024.42.4_suppl.15. - DOI

Publication types

MeSH terms

LinkOut - more resources